Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip M Arlen

Showing results (31-40 of 88) with videos related to

Pageof 9
Sort By:
Reviews in Urology|September 21, 2006
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancerGregory D Leonard, William L Dahut, James L Gulley, et al.
Clinical Prostate Cancer|March 30, 2004
National Cancer Institute intramural approach to advanced prostate cancerPhilip M Arlen, William D Figg, James Gulley, et al.
Cancers|July 9, 2022
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human CarcinomasKwong Yok Tsang, Massimo Fantini, Sharon A Mavroukakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancerJunko Yokokawa, Vittore Cereda, Cinzia Remondo, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 3, 2019
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma CellsMassimo Fantini, Justin M David, Hing C Wong, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2013
Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical modelsSandip Pravin Patel, Andrew Bristol, Olga Saric, et al.
Cancers|October 27, 2022
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201Kwong Y Tsang, Massimo Fantini, Anjum Zaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapyRavi A Madan, James L Gulley, Jeffrey Schlom, et al.
BJU International|December 13, 2006
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to boneShenhong L Wu, Elizabeth Jones, James L Gulley, et al.
Expert Opinion on Biological Therapy|August 30, 2011
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liverJames L Gulley, Ravi A Madan, Kwong-Yok Tsang, et al.
Pageof 9

Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Reviews in Urology|September 21, 2006
Docetaxel and thalidomide as a treatment option for androgen- independent, nonmetastatic prostate cancerGregory D Leonard, William L Dahut, James L Gulley, et al.
Clinical Prostate Cancer|March 30, 2004
National Cancer Institute intramural approach to advanced prostate cancerPhilip M Arlen, William D Figg, James Gulley, et al.
Cancers|July 9, 2022
Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human CarcinomasKwong Yok Tsang, Massimo Fantini, Sharon A Mavroukakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2008
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancerJunko Yokokawa, Vittore Cereda, Cinzia Remondo, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 3, 2019
An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma CellsMassimo Fantini, Justin M David, Hing C Wong, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2013
Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical modelsSandip Pravin Patel, Andrew Bristol, Olga Saric, et al.
Cancers|October 27, 2022
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201Kwong Y Tsang, Massimo Fantini, Anjum Zaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapyRavi A Madan, James L Gulley, Jeffrey Schlom, et al.
BJU International|December 13, 2006
Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to boneShenhong L Wu, Elizabeth Jones, James L Gulley, et al.
Expert Opinion on Biological Therapy|August 30, 2011
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liverJames L Gulley, Ravi A Madan, Kwong-Yok Tsang, et al.
Pageof 9